$Treatment Options in Triple-Class Refractory Multiple Myeloma$

Treatment Options in Triple-Class Refractory Multiple Myeloma

Episodes

Specialty:

All

Year:

All

EP. 1: Treatment Advances in Triple-Class Refractory/Relapsed Myeloma

ByPaul Richardson, MD, Dana-Farber Cancer Institute

January 14th 2021

EP. 2: INN Melphalan Flufenamide in Triple-Class Refractory/Relapsed MM

ByPaul Richardson, MD, Dana-Farber Cancer Institute

January 14th 2021

EP. 3: HORIZON vs MAMMOTH Explored in R/R Multiple Myeloma

ByPaul Richardson, MD, Dana-Farber Cancer Institute

January 14th 2021

EP. 4: RRMM: INN Melphalan Flufenamide/DEX and Extramedullary Disease

ByPaul Richardson, MD, Dana-Farber Cancer Institute

January 14th 2021

EP. 5: RRMM & High-Risk Cytogenetics: INN Melphalan Flufenamide/DEX

ByPaul Richardson, MD, Dana-Farber Cancer Institute

January 14th 2021

EP. 6: INN Melphalan Flufenamide–DEX for Older Patients With RRMM

ByPaul Richardson, MD, Dana-Farber Cancer Institute

January 14th 2021

EP. 7: RRMM: INN Melphalan Flufenamide After Alkylator Therapy

ByPaul Richardson, MD, Dana-Farber Cancer Institute

January 28th 2021

EP. 8: RRMM: Incorporating INN Melphalan Flufenamide Into Clinical Practice

ByPaul Richardson, MD, Dana-Farber Cancer Institute

January 28th 2021

Trending on OncLive

FDA Grants Fast Track Designation to PLN-101095 Plus Pembrolizumab in Solid Tumors

mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC

Dr Skoulidis on First-Line Divarasib Plus Pembrolizumab in KRAS G12C+ NSCLC

Dr Cortés on Developing CD47 as a Biomarker in Pretreated HER2+ Breast Cancer

Enzalutamide Plus Talazoparib Shows Activity in mHSPC